These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 35916272)

  • 1. Plasma mid-regional pro-adrenomedullin: A biomarker of the ischemic penumbra in hyperacute stroke.
    Ishiyama H; Tanaka T; Saito S; Koyama T; Kitamura A; Inoue M; Fukushima N; Morita Y; Koga M; Toyoda K; Kuriyama N; Urushitani M; Ihara M
    Brain Pathol; 2023 Mar; 33(2):e13110. PubMed ID: 35916272
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mid-regional pro-adrenomedullin and lactate levels for risk stratification in patients with out-of-hospital cardiac arrest.
    Zelniker TA; Schwall D; Hamidi F; Steinbach S; Scheller P; Spaich S; Michels G; Giannitsis E; Katus HA; Frey N; Preusch MR
    Eur Heart J Acute Cardiovasc Care; 2023 Jun; 12(6):364-371. PubMed ID: 36943296
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic value of midregional pro-adrenomedullin in patients with acute myocardial infarction: the LAMP (Leicester Acute Myocardial Infarction Peptide) study.
    Khan SQ; O'Brien RJ; Struck J; Quinn P; Morgenthaler N; Squire I; Davies J; Bergmann A; Ng LL
    J Am Coll Cardiol; 2007 Apr; 49(14):1525-32. PubMed ID: 17418290
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma midregional pro-adrenomedullin improves prediction of functional outcome in ischemic stroke.
    Seifert-Held T; Pekar T; Gattringer T; Simmet NE; Scharnagl H; Bocksrucker C; Lampl C; Storch MK; Stojakovic T; Fazekas F
    PLoS One; 2013; 8(7):e68768. PubMed ID: 23894342
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association Between Cerebral Microbleeds and Circulating Levels of Mid-Regional Pro-Adrenomedullin.
    Kuriyama N; Koyama T; Ozaki E; Saito S; Ihara M; Matsui D; Watanabe I; Kondo M; Marunaka Y; Takada A; Akazawa K; Tomida S; Nagamitsu R; Miyatani F; Miyake M; Nakano E; Kobayashi D; Watanabe Y; Mizuno S; Maekawa M; Yoshida T; Nukaya Y; Mizuno T; Yamada K; Uehara R
    J Alzheimers Dis; 2022; 88(2):731-741. PubMed ID: 35694922
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relation between Mid-Regional Pro-Adrenomedullin in Patients with Chronic Heart Failure and the Dose of Diuretics in 2-Year Follow-Up-Data from FAR NHL Registry.
    Špinarová M; Špinar J; Špinarová L; Krejčí J; Goldbergová-Pávková M; Pařenica J; Ludka O; Málek F; Ošťádal P; Benešová K; Jarkovský J; Lábr K
    Medicina (Kaunas); 2022 Oct; 58(10):. PubMed ID: 36295637
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased concentrations of bioactive adrenomedullin subsequently to angiotensin-receptor/neprilysin-inhibitor treatment in chronic systolic heart failure.
    Arfsten H; Goliasch G; Bartko PE; Prausmüller S; Spinka G; Cho A; Novak J; Haslacher H; Strunk G; Struck J; Hülsmann M; Pavo N
    Br J Clin Pharmacol; 2021 Mar; 87(3):916-924. PubMed ID: 32598074
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness of mid-regional pro-adrenomedullin (MR-proADM) as prognostic marker in COVID-19 critically ill patients: An observational prospective study.
    Montrucchio G; Sales G; Rumbolo F; Palmesino F; Fanelli V; Urbino R; Filippini C; Mengozzi G; Brazzi L
    PLoS One; 2021; 16(2):e0246771. PubMed ID: 33556140
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mid-regional pro-adrenomedullin in patients with acute dyspnea: Data from the Akershus Cardiac Examination (ACE) 2 Study.
    Pervez MO; Lyngbakken MN; Myhre PL; Brynildsen J; Langsjøen EC; Høiseth AD; Christensen G; Omland T; Røsjø H
    Clin Biochem; 2017 May; 50(7-8):394-400. PubMed ID: 28065681
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mid-regional pro-adrenomedullin as a prognostic marker in sepsis: an observational study.
    Christ-Crain M; Morgenthaler NG; Struck J; Harbarth S; Bergmann A; Müller B
    Crit Care; 2005; 9(6):R816-24. PubMed ID: 16356231
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of age on the prognostic value of mid-regional pro-adrenomedullin in the general population.
    Brouwers FP; de Boer RA; van der Harst P; Struck J; de Jong PE; de Zeeuw D; Gans RO; Gansevoort RT; Hillege HL; van Gilst WH; Bakker SJ
    Heart; 2012 Sep; 98(18):1348-53. PubMed ID: 22821276
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mid-regional pro-adrenomedullin in the early evaluation of acute chest pain patients.
    Haaf P; Twerenbold R; Reichlin T; Faoro J; Reiter M; Meune C; Steuer S; Bassetti S; Ziller R; Balmelli C; Campodarve I; Zellweger C; Kilchenmann A; Irfan A; Papassotiriou J; Drexler B; Mueller C
    Int J Cardiol; 2013 Sep; 168(2):1048-55. PubMed ID: 23199555
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Does mid-regional pro-adrenomedullin (MR-proADM) improve the sequential organ failure assessment-score (SOFA score) for mortality-prediction in patients with acute infections? Results of a prospective observational study.
    Haag E; Gregoriano C; Molitor A; Kloter M; Kutz A; Mueller B; Schuetz P
    Clin Chem Lab Med; 2021 May; 59(6):1165-1176. PubMed ID: 33554514
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The vasoactive peptide MR-pro-adrenomedullin in COVID-19 patients: an observational study.
    Gregoriano C; Koch D; Kutz A; Haubitz S; Conen A; Bernasconi L; Hammerer-Lercher A; Saeed K; Mueller B; Schuetz P
    Clin Chem Lab Med; 2021 Apr; 59(5):995-1004. PubMed ID: 33554516
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness of mid-regional pro-adrenomedullin, compared to other biomarkers (including lymphocyte subpopulations and immunoglobulins), as a prognostic biomarker in COVID-19 critically ill patients: New evidence from a 15-month observational prospective study.
    Montrucchio G; Sales G; Balzani E; Lombardo D; Giaccone A; Cantù G; D'Antonio G; Rumbolo F; Corcione S; Simonetti U; Bonetto C; Zanierato M; Fanelli V; Filippini C; Mengozzi G; Brazzi L
    Front Med (Lausanne); 2023; 10():1122367. PubMed ID: 37035317
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mid-Regional Pro-Adrenomedullin, Methemoglobin and Carboxyhemoglobin as Prognosis Biomarkers in Critically Ill Patients with COVID-19: An Observational Prospective Study.
    Oblitas CM; Galeano-Valle F; Ramírez-Navarro J; López-Cano J; Monterrubio-Manrique Á; García-Gámiz M; Sancho-González M; Arenal-López S; Álvarez-Sala Walther LA; Demelo-Rodríguez P
    Viruses; 2021 Dec; 13(12):. PubMed ID: 34960714
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systematic review with meta-analysis of mid-regional pro-adrenomedullin (MR-proadm) as a prognostic marker in Covid-19-hospitalized patients.
    Fialek B; De Roquetaillade C; Pruc M; Navolokina A; Chirico F; Ladny JR; Peacock FW; Szarpak L
    Ann Med; 2023 Dec; 55(1):379-387. PubMed ID: 36607317
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adrenomedullin and endothelin-1 are associated with myocardial injury and death in septic shock patients.
    Lundberg OH; Bergenzaun L; Rydén J; Rosenqvist M; Melander O; Chew MS
    Crit Care; 2016 Jun; 20(1):178. PubMed ID: 27282767
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mid-regional pro-atrial natriuretic peptide and pro-adrenomedullin testing for the diagnostic and prognostic evaluation of patients with acute dyspnoea.
    Shah RV; Truong QA; Gaggin HK; Pfannkuche J; Hartmann O; Januzzi JL
    Eur Heart J; 2012 Sep; 33(17):2197-205. PubMed ID: 22645194
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Penumbra quantification from MR SWI-DWI mismatch and its comparison with MR ASL PWI-DWI mismatch in patients with acute ischemic stroke.
    Bhattacharjee R; Gupta RK; Das B; Dixit VK; Gupta P; Singh A
    NMR Biomed; 2021 Jul; 34(7):e4526. PubMed ID: 33880799
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.